Barclays Reaffirms Their Buy Rating on Haleon PLC (HLN)
TipRanks (Wed, 24-Jun 2:09 AM ET)
Advil Challenges Sports Culture's "No Pain No Gain" Mentality This Summer
Business Wire (Tue, 9-Jun 7:00 AM ET)
Market Chameleon (Mon, 8-Jun 5:27 AM ET)
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities
Business Wire (Mon, 8-Jun 5:11 AM ET)
Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.
Business Wire (Thu, 4-Jun 2:32 PM ET)
Market Chameleon (Thu, 4-Jun 4:16 AM ET)
PRNewswire (Wed, 3-Jun 9:42 AM ET)
Globe Newswire (Thu, 21-May 9:59 AM ET)
Globe Newswire (Mon, 4-May 7:00 AM ET)
Business Wire (Tue, 28-Apr 7:00 AM ET)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Haleon PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol HLN.
As of June 24, 2026, HLN stock price climbed to $9.23 with 9,295,484 million shares trading.
HLN has a beta of 0.06, meaning it tends to be less sensitive to market movements. HLN has a correlation of 0.00 to the broad based SPY ETF.
HLN has a market cap of $40.68 billion. This is considered a Large Cap stock.
In the last 3 years, HLN traded as high as $11.42 and as low as $7.70.
The top ETF exchange traded funds that HLN belongs to (by Net Assets): PPH, QLTI, AQEC, AVDE, YLDE.
HLN has underperformed the market in the last year with a return of -10.2%, while the SPY ETF gained +23.4%. In the last 3 month period, HLN fell short of the market, returning -5.7%, while SPY returned +12.2%. However, in the most recent 2 weeks HLN has outperformed the stock market by returning +1.2%, while SPY returned -0.3%.
HLN support price is $8.82 and resistance is $9.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HLN shares will trade within this expected range on the day.